Clinical advances in pulmonary during 2015

doi:10.3969/j.issn.1004-583X.2016.02.004

Abstract

CLC Number:

R563.1

Yuan Yadong, Chen Ye,Wang Li,Shen Lixiao. Clinical advances in pulmonary during 2015[J]. Clinical Focus, 2016, 31(2): 143-150.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.02.004

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I2/143

[1] Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis, 2015, pii: S1473-3099(15)00424-7. [Epub ahead of print].
[2] Dimopoulos G,Poulakou G,Akova M,et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU[J]. Intensive Care Med,2015,41(12): 2057-2075.
[3] 陈佰义,李光辉,倪语星,等.β-内酰胺类抗生素/β-内酰胺酶抑制剂合剂临床应用专家共识[J].中华医学杂志,2015,95(48) :3887-3894.
[4] 中国医药教育协会感染疾病专业委员会,中华结核和呼吸杂志编辑委员会,中国药学会药物临床评价研究专业委员会.抗菌药物超说明书用法专家共识[J].中华结核和呼吸杂志,2015,38(6):410-444.
[5] Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians[J]. Ann Intern Med,2015,163(9):701-711.
[6] Olschewski H, Kovacs. ESC guidelines 2015 on pulmonary hypertension[J].Herz,2015,40(8): 1055-1060.
[7] Maeder MT, Kleiner R, Weilenmann D. Severely worsening dyspnea after initiation of macitentan therapy for pulmonary arterial hypertension[J]. Int J Cardiol,2016,202:244-245.
[8] Hambly N, Granton J. Riociguat for the treatment of pulmonary hypertension. Expert Rev Respir Med,2015,9(6):679-695.
[9] Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension[J]. Turk Kardiyol Dern Ars,2014,42(1):78-94.
[10] Ganesh Raghu, Bram Rochwerg, Yuan Zhang, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline[J]. Am J Respir Crit Care Med,2015,192(5):644.
[11] Raghu G, Anstrom KJ, King TE Jr, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary brosis[J]. N Engl J Med,2012,366(21):1968-1977.
[12] Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary brosis[J]. Chest,2005,128(3):1475-1482.
[13] Noth I, Anstrom KJ, Calvert SB, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary brosis[J]. Am J Respir Crit Care Med,2012,186(1):88-95.
[14] Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary brosis[J]. Eur Respir J,2010,35(4):821-829.
[15] Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Ef cacy and safety of nintedanib in idiopathic pulmonary brosis[J]. N Engl J Med,2014,370(22):2071-2082.
[16] Daniels CE, Lasky JA, Limper AH, et al. Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary brosis: randomized placebo-controlledtrial results[J]. AmJ Respir Crit Care Med,2010,181(6):604-610.
[17] Moorhouse RC, Webb DJ, Kluth DC, et al. Endothelin antagonism and its role in the treatment of hypertension[J]. Curr Hypertens Rep,2013,15(5):489-496.
[18] Jackson RM, Glassberg MK, Ramos CF, et al. Sildena l therapy and exercise tolerance in idiopathic pulmonary brosis[J]. Lung,2010,188(2):115-123.
[19] Zisman DA, Schwarz M, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildena l in advanced idiopathic pulmonary brosis[J]. N Engl J Med,2010,363(7):620-628.
[20] Han MK, Bach DS, Hagan PG, et al. Sildena l preserves exercise capacity in patients with idiopathic pulmonary brosis and rightsided ventricular dysfunction[J]. Chest,2013,143(6):1699-1708.
[21] Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary brosis: an analysis of data from three randomised controlled trials[J]. Lancet Respir Med,2013,1(5):369-376.
[22] Martinez FJ, de Andrade JA, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary brosis[J]. N Engl J Med,2014,370(22):2093-2101.
[23] Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update[J]. J Clin Oncol,2015,33(30):3488-515.
[24] Ettinger DS, Wood DE, Akerley W, et al. Non-Small Cell Lung Cancer, Version 6.2015[J]. J Natl Compr Canc Netw,2015,13(5):515-524.
[25] 中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟专家组.肺部结节诊治中国专家共识[J].中华结核和呼吸杂志,2015,38(4):249-254.
[26] Vilmann P,Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS)[J]. Endoscopy,2015,47(6):c1.
[27] Sharma A, Menche J, Huang CC, et al. A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma[J]. Hum Mol Genet,201,24(11):3005-3020.
[28] Wang Y, Yang L, Li P, et al. Circulating microRNA signatures associated with childhood asthma[J]. Clin Lab,2015,61(5/6): 467-474.
[29] Sonnenschein-van der Voort, AM, Arends, LR, de Jongste, JC et al. Preterm birth, infant weight gain, and childhood asthma risk: a meta-analysis of 147,000 European children[J]. J Allergy Clin Immunol,2014,133(5): 1317-1329.
[30] Huang L, Chen Q, Zhao Y, et al. Is elective cesarean section associated with a higher risk of asthma A meta-analysis[J]. J Asthma,2015,52(1): 16-25.
[31] 慢性阻塞性肺疾病诊治专家组.祛痰/抗氧化药治疗慢性阻塞性肺疾病中国专家共识[J].国际呼吸杂志,2015,35(16):1201-1209.

Clinical advances in pulmonary during 2015

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Lei, Li Mingwu, Wan Rong. Diagnostic value of laboratory indexes in patients with pulmonary tuberculosis complicated by pulmonary embolism [J]. Clinical Focus, 2024, 39(2): 134-139.
[2]	Hou Wei, Zhang Lijun, Zhang Man, Wang Yakun, Tian Liyuan. Epidemiological investigation of adenovirus respiratory tract infection in hospitalized children [J]. Clinical Focus, 2022, 37(10): 916-920.
[3]	Cui Lu, Li Jing, Liu Yuhong. Primary Sjögren’s syndrome with pulmonary embolism:a case report and literature review [J]. Clinical Focus, 2021, 36(4): 361-364.
[4]	Huang Ping, Liu Hanyun, Li Yuhong. Risk factors of lung cancer with pulmonary embolism:a meta-analysis [J]. Clinical Focus, 2021, 36(12): 1061-1066.
[5]	Li Shuangping, Mao Yimin, He Xuegai. Diagnostic value of modified Wells score in lung cancer complicated with venous thromboembolism [J]. Clinical Focus, 2020, 35(5): 421-424.
[6]	Shi Zhimin, Zhang Tongqiang, Guo Wei, Ren Lixin, Meng Zhaowei, Xu Yongsheng. A case report of mycoplasma pneumoniacombined pulmonary thromboembolism in child [J]. Clinical Focus, 2019, 34(8): 748-751.
[7]	Qiu Yi, Chen Lu, Qu Meidi, Zhang Min, Gu Hongliu, Sha Qi. Effect of nutritional status on nausea and vomiting caused by chemotherapy in patients with lung cancer [J]. Clinical Focus, 2019, 34(6): 549-552.
[8]	Yuan Boyun, Liu Xin, Yuan Yadong. Part of advances in respiratory disease during 2018 [J]. Clinical Focus, 2019, 34(1): 49-55.
[9]	Chen Benchao, Li Heng, Xiang Xudong, Li Gaofeng, Fu Feng, Guo Qi，Fan Shengliang，Wang Deguang. Efficacy and safety of icotinib combined with radiotherapy in the treatment of lung cancer with brain metastasis: a metaanalysis [J]. Clinical Focus, 2018, 33(8): 705-710.
[10]	Yuan Boyun， Gong Xiaowei， Yuan Yadong. Major advances in respiratory diseases during 2017 [J]. Clinical Focus, 2018, 33(1): 16-22.
[11]	Yang Xiuchun， Li Yue， Xiao Bing. Common problems and solutions of temporary cardiac pacemaker implantation [J]. Clinical Focus, 2017, 32(6): 469-471.
[12]	Yuan Yadong， Shen Lixiao， Wang Li， Cao Yi. Clinical advances in respiratory diseases during 2016 [J]. Clinical Focus, 2017, 32(2): 132-138.
[13]	Cui Xianglia， Wan Ziruia， Hou Kelua， Wang Zihuia， Ma Zhuoa， Kuang Tuguangb， . Clinical feature of 95 cases in malignant tumor with pulmonary embolism [J]. Clinical Focus, 2017, 32(12): 1041-1044.
[14]	Cai Jingjing1，2， Miao Jianlong1， Zhou Jinhua1， Zhang Yingying1，2， Liu Ruijuan1. Clinical features of chronic obstructive pulmonary disease with lung cancer [J]. Clinical Focus, 2017, 32(12): 1065-.
[15]	Yang Jiping, Niu Caihong, Qi Jinchong, Yang Bei, Xiu Baoxin, Cao Qizhen, Song Peng, Geng Zuojun. Qualitative estimation of right ventricular function and pulmonary artery obstruction degree after acute pulmonary embolism with computed tomographic pulmonary angiography [J]. Clinical Focus, 2016, 31(4): 407-410.